Dig V.K. Yarlagadda

Developmental reversion underlies resistance to immune checkpoint blockade in kidney cancer

Despite the clinical success of immune checkpoint inhibitors (ICIs) in the management of advanced clear cell renal cell carcinoma (ccRCC), many tumors develop acquired resistance, presumed to arise from a refractory subpopulation of persister cancer cells. Previous studies have provided insights into tumor microenviron...